Biotechnology company Akari Therapeutics and biopharmaceutical company Peak Bio have announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!